"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase ...

Camrelizumab is under clinical development by Elevar Therapeutics and currently in Pre-Registration for Hepatocellular Carcinoma.

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

However, the contribution of FA metabolism reprogramming to the heterogeneity of hepatocellular carcinoma (HCC) has not been established. This article describes how bioinformatics analysis using ...

Serious liver and nonliver outcomes linked to metabolic dysfunction–associated steatotic liver disease were different between ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.